A prospective study to investigate the effect of CBM558 combined with pembrolizumab on gut microbiota and prognosis in patients with advanced urothelial carcinoma.

Taguchi Satoru0 个研究点目标入组 30 人开始时间: 2023年3月9日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) With unresectable (recurrent, locally advanced, or metastatic) urothelial cancer (bladder, ureters, and urethra cancer)
•(2) With cancer progression after chemotherapy, intolerance to chemotherapy or ineligible for chemotherapy
•(3) With lesion which is measurable based on RECIST 1.1
•(4) Scheduled to take pembrolizumab
•(5) Aged 18 years and above at the time of informed consent
•(6) Male or female
•(7) Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation

•(1) With a history of allergy to pembrolizumab or components of butyrate-producing probiotics
•(2) Taking butyrate-producing probiotics and unable to have washout period of above 5 days prior to experimental treatment
•(3) Pregnant or possible pregnant
•(4) Lactating female
•(5) Judged as ineligible by clinical investigators

发起方

Taguchi Satoru